Chronic Subdural Hematoma as a Geroscience Disease
Current understanding
Chronic subdural hematoma (CSDH) — the commonest neurosurgical condition of older adults — is reframed in a 2026 minireview as a geroscience disease whose dural neomembrane biology and recurrence risk map onto the twelve hallmarks of aging, with chronic inflammation and altered intercellular communication nominated as the strongest contributors and senolytics/other gerotherapeutics proposed as mechanism-directed candidates [expert-opinion]. No gerotherapeutic has been tested against CSDH endpoints; the proposal is a research agenda, not a treatment claim, and the standard caveat about mechanism-to-human translation failures applies.
Evidence log
- 2026-07-11 — Chronic subdural hematoma as failed resolution at the aged dura-subdural interface: Immune-vascular mechanisms, biomarker interpretation, and therapeutic translation.: 2026 review reframes CSDH persistence/recurrence as failed resolution at the aged dura-subdural interface — a local immune-vascular-fibrinolytic niche shaped by frailty, immune aging, and vascular aging — rather than retained clot or technical failure, and lays out a biomarker/therapy agenda that remains conceptual with no new primary data. [expert-opinion] (novelty: 3)